<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322179</url>
  </required_header>
  <id_info>
    <org_study_id>CHR0036</org_study_id>
    <secondary_id>PEG215</secondary_id>
    <nct_id>NCT00322179</nct_id>
  </id_info>
  <brief_title>Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C</brief_title>
  <official_title>Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palo Alto Veterans Institute for Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Palo Alto Veterans Institute for Research</source>
  <brief_summary>
    <textblock>
      The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in
      patients who are obese. However, it is not clear whether this is related to suboptimal dosing
      of the medication or alterated response in obese patients. Alterated immune response had been
      reported in obese patients. The goal of current study is to determine the immune response to
      interferon in obese compared to non-obese chronic hepatitis C in an tissue culture system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To examine our hypothesis, we will incubate PBMC samples from obese and nonobese patients
      with IFN, followed by microarray analysis to compare the IFN response patterns in both groups
      of patients and to identify genes differentially regulated between these two groups.
      Identification of such genes will provide important insight to the mechanism of the antiviral
      effect of HCV. The identified genes will have the potential of serving as targets for
      pharmaceutical intervention aiming at enhancing the efficacy of IFN therapy for obese
      patients.

      This is an open-label study. Ten obese and 10 nonobese patients with chronic hepatitis C will
      be recruited. For the purpose of this study, obese is defined as body weight &gt;85 kg and BMI
      &gt;30, and nonobese as body weight &lt;75 kg and BMI&lt;25.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">22</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Obese</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion Criteria:

          -  obese (weight &gt; 85kg and BMI&gt;30) or non-obese patients (&lt;75kg and BMI &lt;25) with
             chronic Hepatitis C

          -  Chronic Hepatitis C infection with documented HCV RNA

          -  Body habitat either as obese or non-obese as defined above

          -  Currently not under IFN therapy

          -  Non-African American
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  obese (weight &gt; 85kg and BMI&gt;30) or non-obese patients (&lt;75kg and BMI &lt;25) with
             chronic Hepatitis C

          -  Chronic Hepatitis C infection with documented HCV RNA

          -  Body habitat either as obese or non-obese as defined above

          -  Currently not under IFN therapy

          -  Non-African American

        Exclusion Criteria:

          -  Body habitat neither obese or non-obese as defined for the purpose of this study

          -  Unable to give consent

          -  On immunomodulatory agents such as prednisone

          -  Active infection other than Hepatitis C

          -  Co-infection with HBV or HIV

          -  Active or excessive alcohol use

          -  Other cause of chronic Hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramsey Cheung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Palo Alto Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003 Sep;38(3):639-44.</citation>
    <PMID>12939590</PMID>
  </reference>
  <reference>
    <citation>Camps J, Crisóstomo S, García-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut. 1993 Dec;34(12):1714-7.</citation>
    <PMID>7904252</PMID>
  </reference>
  <reference>
    <citation>Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002 Oct;110(8):1093-103.</citation>
    <PMID>12393845</PMID>
  </reference>
  <reference>
    <citation>Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.</citation>
    <PMID>12324553</PMID>
  </reference>
  <reference>
    <citation>Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology. 2003 Mar;37(3):610-21. Erratum in: Hepatology. 2003 Jun;37(6):1503.</citation>
    <PMID>12601359</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2006</study_first_submitted>
  <study_first_submitted_qc>May 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2006</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <name_title>Stephen J. Rossi, PharmD</name_title>
    <organization>Roche Laboratories</organization>
  </responsible_party>
  <keyword>Microarray Analysis</keyword>
  <keyword>Obesity</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

